This phase 2/3 randomized controlled trial compared three types of cell injections (autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, and allogeneic human umbilical cord tissue-derived mesenchymal stromal cells) to corticosteroid injection for knee osteoarthritis. At 1 year, none of the cell therapies showed superiority over corticosteroid injection in reducing pain or improving function, based on visual analog scale and Knee injury and osteoarthritis outcome score pain scores. No serious adverse events were reported.
Publisher
Nature Medicine
Published On
Dec 29, 2023
Authors
Ken Mautner, Michael Gottschalk, Scott D. Boden, Alison Akard, Won C. Bae, Lora Black, Blake Boggess, Paramita Chatterjee, Christine B. Chung, Kirk A. Easley, Greg Gibson, Josh Hackel, Katie Jensen, Linda Kippner, Chad Kurtenbach, Joanne Kurtzberg, R. Amadeus Mason, Benjamin Noonan, Krishnendu Roy, Verle Valentine, Carolyn Yeago, Hicham Drissi
Tags
knee osteoarthritis
cell therapy
corticosteroid
pain reduction
function improvement
clinical trial
adverse events
Related Publications
Explore these studies to deepen your understanding of the subject.
